Methods and products for transfecting cells

Abstract

The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.

1 .- 61 . (canceled) 
     
     
         62 . A method for treating sickle cell disease or β-thalassemia in a human subject, comprising:
 (a) harvesting a hematopoietic cell from the subject; 
 (b) gene-editing the hematopoietic cell by transfecting the hematopoietic cell with an in vitro transcribed synthetic RNA molecule encoding a gene-editing protein, wherein
 the hematopoietic cell expresses the gene-editing protein, and 
 the gene-editing protein comprises a DNA-binding domain and a nuclease catalytic domain that causes a single-strand or double-strand break in the DNA of the hematopoietic cell to reduce the function of a HBB gene; and 
 
 administering the gene-edited hematopoietic cell to the subject to result in the treatment of sickle cell disease or β-thalassemia in the subject. 
 
     
     
         63 . The method of  claim 62 , wherein the gene-editing protein is selected from a TALEN and a zinc finger nuclease. 
     
     
         64 . The method of  claim 62 , wherein the in vitro transcribed synthetic RNA molecule further comprises one or more of a 5′-cap, a 5′-cap 1 structure, and a 3′-poly(A) tail. 
     
     
         65 . The method of  claim 62 , wherein the double-strand break is within about 5,000,000 bases of the transcription start site of the HBB gene. 
     
     
         66 . The method of  claim 62 , wherein the hematopoietic cell is a hematopoietic stem cell. 
     
     
         67 . The method of  claim 62 , wherein the hematopoietic cell is a white blood cell.